New pill targets hard-to-treat pancreatic cancer gene

NCT ID NCT07589569

Recruiting now Disease control Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called HRS-7058 in people with advanced pancreatic cancer that has a specific mutation in the KRAS gene (G12C). Participants must have already tried at least one prior treatment. The goal is to see if the drug can shrink tumors and how safe it is. About 92 adults aged 18 to 75 will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, 210003, China
Tianjin Medical University Cancer Institute & Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.